I-Sarcoma, eyenzeka kubantu abasha futhi iyisigaxa esibi esivela kwizicubu ze-mesenchymal (kufaka phakathi izicubu zomzimba nezicubu). AmaSarcomas ayingozi kakhulu futhi akhula ngokushesha! Ama-sarcomas ajwayelekile afaka i-osteosarcoma, leiomyosarcoma, lymphosarcoma, ne-synovial sarcoma. I-Leiomyoma, i-lymphosarcoma, ne-synovial sarcoma ingakha i-metastases yegazi zisencane.
Indlela ekhethwayo ye-sarcoma ukuhlinzwa. Ukuze kutholakale ukwelashwa okuqinile, odokotela basekhaya ngokuvamile badinga ukuba iziguli zinqunywe izitho zomzimba. Kodwa-ke, okwamanje kunzima ukwelapha i-liposarcoma engalungiseki noma ethuthukisiwe kanye ne-leiomyosarcoma eyenzeka ngemuva kwe-peritoneum futhi ibe nezimila ezinkulu. Izibhedlela ekhaya naphesheya zivame ukugcina izitho eziningi bese zenza i-radiotherapy.
I-Sarcoma ayizweli emithini ye-chemotherapy! Ukusebenza kahle kwe-radiotherapy yendawo nakho akusebenzi kahle, kodwa uma ama-metastase emaphashini engasebenzi kahle.
I-Palbociclib capsule iyi-inhibitor ekhetha kakhulu ye-cyclin-dependent kinases CDK4 ne-CDK6. Futhi umdlavuza webele wokuqala immunotherapy inhibitor to be approved by the US FDA. Palbociclib capsules are targeted drugs for the treatment of sarcoma.
Isebenza kanjani iPalbociclib: Wonke amangqamuzana aphilayo ahlukaniswa ngamaseli, kanti iPalbociclib ingavimbela ngempumelelo inqubo yokuhlukaniswa kwamaseli, futhi ukuhlanganisa iPalbociclib nezinye izindlela zokwelapha ezilwa nomdlavuza ezifana ne-endocrine therapy, chemotherapy, kanye nezinye izindlela zokwelashwa ezihlosiwe zingaphatha izinhlobo eziningi zomdlavuza Khiqiza amandla amakhulu ukuphulukisa umphumela.
Ukwelashwa okuhlosiwe kungasebenzisa izidakamizwa ezahlukahlukene nokunye ukungenelela ukukhomba ngokunembile nokuhlasela amaseli omdlavuza ngaphandle kokulimaza amaseli ajwayelekile. UDkt. Peter J. O'Dwyer uthe ngaphezu kwama-neutrophils, iPalbociclib ine-The effect yamaseli nayo incane, futhi umuthi ungavimbela ngempumelelo ukukhula kwezimila kwizicubu. Njengoba sithola imisebenzi emisha ye-CDK4 / 6 eqondisiwe, singathuthukisa inhlanganisela yezidakamizwa ezintsha njengama-anti-cancer aqhamukayo.
Ngokwemiphumela yocwaningo kanye nemiphumela yocwaningo lokuqala lwemitholampilo eshicilelwe ososayensi eNyuvesi yasePennsylvania kujenali i-JAMA Oncology, imiphumela yesigaba sesi-2 sokuhlolwa komtholampilo kweziguli ezingama-29 ze-sarcoma ikhombisa ukuthi umuthi i-Palbociclib ungafinyelela ukusinda okungathuthuki okumaphakathi kwabangama-66. % yeziguli amasonto angu-12. I-Palbociclib iyasebenza ekwelapheni i-sarcoma futhi ingandisa isikhathi sokuphila ngaphandle kokuqhubekela phambili kweziguli.
